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ORIGINAL ARTICLE
Epigenetic regulation of RNA polymerase III transcription in
early breast tumorigenesis
J-L Park1,2,12, Y-S Lee3,12, M-J Song4, S-H Hong3, J-H Ahn5, E-H Seo1,2, S-P Shin6, S-J Lee6, BH Johnson7, MR Stampfer8, H-P Kim4,9,10,
S-Y Kim1,2 and YS Lee7,11
RNA polymerase III (Pol III) transcribes medium-sized non-coding RNAs (collectively termed Pol III genes). Emerging diverse roles of
Pol III genes suggest that individual Pol III genes are exquisitely regulated by transcription and epigenetic factors. Here we report
global Pol III expression/methylation proﬁles and molecular mechanisms of Pol III regulation that have not been as extensively
studied, using nc886 as a representative Pol III gene. In a human mammary epithelial cell system that recapitulates early breast
tumorigenesis, the fraction of actively transcribed Pol III genes increases reaching a plateau during immortalization. Hyper-
methylation of Pol III genes inhibits Pol III binding to DNA via inducing repressed chromatin and is a determinant for the Pol III
repertoire. When Pol III genes are hypo-methylated, MYC ampliﬁes their transcription, regardless of its recognition DNA motif. Thus,
Pol III expression during tumorigenesis is delineated by methylation and magniﬁed by MYC.
Oncogene advance online publication, 28 August 2017; doi:10.1038/onc.2017.285
INTRODUCTION
RNA polymerase III (Pol III) transcribes medium-sized ncRNAs and
short interspersed elements such as Alu and MIR (mammalian-
wide interspersed repeats). Many Pol III-transcribed ncRNAs
(termed ‘Pol III genes’ hereafter), for example, 5S rRNA and
transfer RNAs (tRNAs), have fundamental roles in cell growth. Early
studies indicated that Pol III transcription is elevated in cancer,
because the Pol III machinery is suppressed by tumor suppressors
such as p53, Rb, PTEN or activated by the MYC oncogene
(reviewed in White1). Among them, MYC is thought to have an
extensive impact on the expression of Pol III genes in cancer,
because it is the master transcription factor (TF) that ampliﬁes the
expression of a signiﬁcant number (415% of total) of genes when
it is overexpressed in a number of malignancies (reviewed in
Dang2). MYC activates classic Pol III genes 5S rRNA and tRNA.3,4
Epigenetic regulation, especially chromatin structure, has a
critical role in the expression of Pol III genes (reviewed in
Bhargava5 and Park et al.6). Although CpG methylation is the most
common epigenetic modiﬁcation on DNA, silencing of Pol III
genes by methylation has not been examined thoroughly in
contrast to the abundant knowledge of Pol II genes (reviewed in
Klose and Bird7). Although the transcription of tRNAs and U6
snRNA has been shown to be inhibited by methylation,8,9 the
biological signiﬁcance of such suppression is questionable
because these RNAs have indispensable cellular functions.
Besides fundamental biological roles of classic Pol III genes,
their unconventional roles as well as new Pol III genes are
emerging (reviewed in Hu et al.10). We have recently identiﬁed a
Pol III gene, called nc886, whose silencing by CpG hyper-
methylation is of prognostic signiﬁcance in several
malignancies.11–14 nc886 is the ﬁrst such case among Pol III
genes. In addition to nc886, a signiﬁcant fraction of Pol III genes is
expected to be silenced in various normal and pathological
conditions. For example, Alu and viral ncRNAs are shown to be
suppressed by methylation15–19 and their silencing is of biological
signiﬁcance in maintaining the stability of the human genome and
as a viral defense mechanism. Another example is tRNA cleavage
products that play gene-regulatory functions in a sequence-
speciﬁc manner (reviewed in Fu et al.20). Thus, selective expression
of a subset of tRNAs from a total of 608 tRNA-coding loci in the
human genome could be crucial in certain biological contexts.
However, an extensive study on Pol III regulation has been
hampered by some technical issues. Transcription units of many
Pol III genes are identical or have highly similar sequences that are
scattered throughout the genome in multiple copies. Therefore, it
is challenging to correlate the transcription rate from a single
genomic locus to the steady-state RNA level. For example, the
regulation of individual Pol III transcription units by methylation
and MYC has not been scrutinized, leaving important questions
yet to be answered. Does MYC activate all Pol III genes or
speciﬁcally activate the ones with the MYC recognition motif (E-
box)? Is hypo-methylation a pre-requisite? How do methylation
and/or MYC shape the Pol III gene expression pattern and how is it
re-shaped during tumorigenesis?
For an in-depth study of molecular events during the human
tumorigenesis, a cell-based model system is essential. A good
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model should reﬂect in vivo events and should yield reproducible
experimental data. Human tissue samples isolated in vivo have a
limited proliferation capability, which imposes problems in
obtaining enough quantities of experimental material for reliable
results and precludes repeating experiments. In vitro cancer cell
lines may have too many genomic abnormalities to provide data
that reﬂect an in vivo situation. In addition, most cell lines lack
genuine normal cell counterparts, and it is often difﬁcult to discern
which features are cancer-speciﬁc. Despite the limited availability
of human-derived material, breast tissues are exceptional in that
large quantities of normal tissues can be obtained through
reduction mammoplasty and mastectomy surgeries and thus
human mammary epithelial cell (HMEC) cultures could be
established.
Primary cells isolated from normal breast tissues (184D in
Figure 1a, 240L and 122L in Supplementary Figure S1A) have a
ﬁnite life span and in order to become immortalized must
overcome or bypass two tumor suppressive barriers: the ‘stasis
barrier’ ( = stress-associated senescence) and the ‘immortalization
barrier’ ( = replicative senescence) (reviewed in Stampfer et al.21).
These two barriers can be overcome by various means: (1) Stasis
can be overcome by errors in the Rb pathway, such as loss of
p16INK4a expression or overexpressed cyclin D1, which can be
accomplished by treatment with a chemical mutagen like benzo
(a)pyrene (BaP), transduction of shRNA to p16 or of a cyclin D1:
cdk2 construct, or errors generated by inactivation of the p53
tumor suppressor or dysregulated MYC expression. (2) Replicative
senescence can be overcome by expression of sufﬁcient
telomerase activity to maintain telomere length, which can be
accomplished by transduction of the MYC oncogene or unknown
errors generated by telomere dysfunction. In some cases, these
treatments can yield immortalized cell lines with additionally
acquired malignant properties, such as anchorage-independent
growth or tumorigenicity in immunosuppressed mice; anchorage-
independent growth can also be conferred to non-malignant
immortal lines by transduction of the mutated ErbB2 oncogene
(Figure 1a).22–27 Primary, immortalized and malignant cells in this
study are designated respectively in green, purple and red letters;
these color codes will be used throughout all ﬁgures. Having
developed from normal tissues, HMEC cultures are an ideal in vitro
cell line model recapitulating early events of breast
tumorigenesis21 (see also http://hmec.lbl.gov/mock/history.html).
Herein, as a ﬁrst step to elucidate Pol III regulation in cancer, we
have investigated the Pol III transcription and methylation in a
HMEC culture system.21 We have also studied the molecular
mechanism as to how methylation and MYC regulate Pol III
transcription, by using nc886 as a representative Pol III gene.
Figure 1. Pol III transcriptome in nine HMEC cultures. (a) Diagram illustrating the HMEC progression series derived from reduction
mammoplasty specimen 184. (b) A pie chart of 4553 candidate Pol III genes (left panel) and 924 that were occupied by Pol III in at least one
HMEC culture in our POLR3A ChIP-seq data (right panel). The full information on individual Pol III genes is in Supplementary Table S1 and S2.
(c) Number of POR3A-occupied Pol III loci in the nine HMEC cultures derived from specimen 184. (d) A bar chart illustrating fractions of
‘genuine Pol III genes’ and ‘pseudogenes and repeats’. See Supplementary Table S1 and S2 for full information. (e) A box plot of normalized Pol
III occupancy per each locus in the nine 184-derived cultures. 10 000 000 of tags were used for normalization among cultures during the
calculation of relative Pol III signal from POLR3A ChIP-seq reads. The analysis of variance (ANOVA) test was used to calculate a P-value. (f) A bar
chart illustrating fractions of Pol III-occupied tRNA genes in a total of 608 tRNA loci (see Supplementary Table S3 for full information).
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RESULTS
Landscape of global expression of Pol III genes (Pol III
transcriptome) in HMEC cultures
To study epigenetic regulation of Pol III transcription during early
tumorigenesis, we examined the Pol III transcriptome in nine
HMEC cultures of the isogenic progression series derived from
normal ﬁnite specimen 184 HMEC. RNA-sequencing is not an
adequate method for Pol III genes, because their repetitive nature
hampers the mapping of seq reads to genomic loci. Therefore,
Chromatin ImmunoPrecipitation followed by high-throughput
sequencing (ChIP-seq) is commonly used as it captures ﬂanking
genomic sequences, which provide a unique sequence tag for
mapping. We employed ChIP-seq of POLR3A, a Pol III catalytic
subunit, as a proxy marker for Pol III transcription.
For ChIP-seq data analysis, we curated a list of 4553 candidate
Pol III loci (Supplementary Table S1) by assembling a list from a
previous report28 and the tRNA database (http://gtrnadb.ucsc.edu/).
These loci included known Pol III genes as well as the Alu and MIR
repeat elements (Figure 1b). Some Pol III genes (BC200, nc886,
vault RNAs (vtRNAs), RNaseMRP_RNA, RNaseP_RNA and SRP_RNA)
are encoded at unique or a few loci, whereas others (5S rRNA,
tRNAs, U6 snRNA, 7SK_RNAs, 7SL_RNAs and Y_RNAs) are present
at4100 loci. In the latter case, only a minor fraction of them can
produce full length transcripts ( = genuine Pol III genes), whereas a
majority of them are pseudogenes. Although these pseudogenes
could be regarded as repeat elements, we followed their original
annotation and did not classify them separately as a repeat
element in the pie chart (Figure 1b), except for tRNAs. We
regarded 608 loci in the tRNA database to be genuine tRNA genes
and distinguished them from the other tRNA-like sequences that
were classiﬁed as a repeat element (Figure 1b). During data
analysis, we paid special attention to tRNA genes, because they
are well deﬁned and curated as compared with other Pol III genes.
From the raw ChIP-seq reads, we considered POLR3A peaks
above a cutoff threshold (Poisson P-value o1.00e-04 and more
than fourfold enrichment relative to input DNAs) to be signiﬁcant
and mapped them at the 4553 candidate Pol III loci. The validity of
our ChIP-seq experiments and data processing were assured by
several facts. First, the number of Pol III peaks mapped at the 4553
loci ranged from 241 to 468 in the nine 184-derived HMEC
cultures (Figure 1c) and these numbers were comparable to
previously reported numbers.28–33 Second, when we analyzed the
924 loci that were Pol III-occupied in at least one HMEC
(Supplementary Table S2), most of the genuine Pol III genes were
included, whereas pseudogenes and repeats were largely
excluded (Figure 1d). Third, the peaks were present at anticipated
correct positions, as shown for nc886 and three vtRNAs as
representative examples (Supplementary Figures S2A–D). Fourth,
POLR3A ChIP-seq signals of nc886, a Pol III gene to be scrutinized
later in this study, across the nine HMEC cultures were consistent
with our Northern or quantitative reverse transcriptase-PCR
data (Supplementary Figure S3; compare Figures 3a and b to be
shown later).
The extent of Pol III occupancy, as indicated by the number of
occupied Pol III loci (Figure 1c) and the relative Pol III signal
estimated from seq reads (Figure 1e), was lower in normal primary
184D than any other HMEC lines, in agreement with the elevated
Pol III activity during tumorigenesis in previous studies (reviewed
in White1). This tendency was also seen in tRNA expression; 154
tRNA loci were bound by Pol III in 184D and this number nearly
doubled in immortalized and malignant HMEC cultures (Figure 1f
and Supplementary Figure S4A).
We further examined tRNA data. The extent of Pol III occupancy
was increased during immortalization, but there was no further
increase following malignant transformation (Figure 1f and
Supplementary Figures S4A–B; compare HMEC cultures in purple
and red letters). A feature of the genomic organization of human
tRNA genes is the chr6 cluster (chr6: 26286753-28956860 in hg19)
where 157 tRNA loci are housed within a region spanning about
2.5 mega-base pair. A majority of tRNA genes in this cluster were
utilized in immortalized and malignant HMEC cultures (Figure 1f).
According to the Pol III occupancy, we classiﬁed tRNAs
(Supplementary Figure S4C and Supplementary Table S3); 78
tRNAs expressed in all nine HMEC cultures, 207 tRNAs in 1 ~ 7
cultures and 210 tRNAs in none of them. The 78 constitutive tRNAs
included a minimum set of 31 tRNAs necessary for decoding 61
codons to all 20 amino acids. Collectively from our data, the tRNA
expression during early tumorigenesis was construed as follows:
Primary cells express a set of tRNAs, small yet enough for the
decoding role. As cells become immortalized, more tRNA genes
are transcribed from the chr6 cluster and also other loci. No
further increase seems to occur after immortalization. Some tRNAs
are speciﬁcally expressed in individual HMEC cultures, and we
speculate that those might play additional roles such as a gene-
regulatory function upon their cleavage.
The global CpG methylation proﬁle (methylome) and its impact on
the Pol III transcriptome in HMEC
To compare expression data with methylation data, we obtained
the methylome from the nine 184-derived HMEC cultures. Out of a
total of 866 895 CpG sites in the methylation array, 3169 were
localized in the 4553 Pol III loci (and ± 300 bp). When we examined
in the 924 loci that were actually bound by Pol III (in at least one
HMEC line), 1421 CpG sites were mapped in 489 loci, with some
individual Pol III loci having multiple CpG sites (Supplementary
Table S4). We sorted the 1421 CpG sites into four groups
according to their methylation values (an average of the nine
HMEC cultures), compared with the POLR3A ChIP-seq signal, and
found that higher methylation was associated with lower Pol III
binding (Figure 2a).
This inverse correlation was also seen in a scatter plot between
Pol III binding and methylation (an average methylation value if a
locus has multiple CpG sites) (Figure 2b and Supplementary Table
S5). In this chart, we noticed that data points were enriched in
three areas (colored boxes in Figure 2b), except for few loci that
were bound by Pol III despite hyper-methylation (designated by
red color in Figure 2b) and identiﬁed to be some tRNA genes.
Although these outliers are intriguing, we focused on the general
propensity in interpreting data. The bulk of transcriptionally active
Pol III loci were hypo-methylated (red-boxed) and were mostly
composed of genuine Pol III genes. Inactive loci were hyper- or
hypo-methylated (green- and blue-boxed, respectively) and
contained most of the repeats and pseudogenes (Figure 2c).
Inactive loci despite hypo-methylation could be partly explained
by defective promoter elements in most pseudogenes. Also, the
scatter plot of the repeats and pseudogenes indicated that most
loci were inactive regardless of their methylation status, in
contrast to the signiﬁcant anti-correlation (Pearson’s r=− 0.6795)
of genuine Pol III genes (Figure 2d). We further split the data into
the six Pol III categories (see Figure 1b), plotted each of them and
conﬁrmed signiﬁcant anti-correlation in tRNAs, U6 snRNA and
others (Supplementary Figures S5A–C). In contrast, such anti-
correlation was not seen in 5S rRNA, Alu and MIR repeats, and
tRNA-like repeats (Supplementary Figures S5D and F). In the case
of 5S rRNA, only two loci were genuine transcripts, but the
remaining 23 loci were pseudogenes. We scrutinized these two
loci and found them to be expressed in 184AA3 and 184FMY2
lines, but to be constitutively hyper-methylated even in these
HMEC cultures (Supplementary Figure S6A–B). So, the expression
of 5S rRNA could not be attributed to methylation and our data
support a classic report in which 5S rRNA expression is not
inhibited by methylation.8 Of course, inspection of many other loci
would be needed to make a concrete conclusion. Our data also
corroborated previous papers having reported inhibition of tRNAs
nc886 regulation by MYC and CpG methylation
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and U6 snRNA by methylation.8,9 Collectively, we proved the
inhibition of genuine Pol III genes by methylation. In the case of
repeats and pseudogenes, we surmise that their hyper-
methylation was coincidental but not causative for their defective
Pol III binding. So, our result was supportive to a recent paper that
showed no effect of methylation on silencing of short interspersed
element repeat elements.19
Pol III genes with nearby Pol II genes tended to be active
(Supplementary Figure S7A), in agreement with a number of
reports.19,28–30,32–34 This correlation could be explained by
methylation. CpG islands, blocks of sequence with a high
frequency of CpG dinucleotides, are usually hypo-methylated
and located near Pol II genes, especially house-keeping genes
(reviewed in Deaton and Bird35). Also in our data, Pol III genes
around a CpG island as well as the neighboring shore/shelf
(located o4 kb from an island) had an inclination to be located in
proximity of Pol II genes (Supplementary Figure S7B) and to be
hypo-methylated (Supplementary Figures S7C and D), as com-
pared with the open sea (located 44 kb away from an island).
Taken together with our earlier data having shown the anti-
correlation between methylation and expression of Pol III genes
(Figures 2a and b), this analysis suggested that the expression of
Pol III genes is dictated by the distribution of CpG islands and their
methylation status, rather than the transcription per se of nearby
Pol II genes.
Thus far we had used average values of the nine HMEC cultures
to elucidate an overall relation between methylation and
expression. Next, we analyzed individual values to cross-
compare between the different HMEC cultures. To reasonably
calculate a Pearson correlation between methylation and expres-
sion across the nine HMEC cultures, we made a shortlist of 137
CpG sites whose nine methylation values had a standard
deviation415% and corresponding Pol III locus had a Pol III
signal in ⩾ 3 HMEC lines. The 137 Pearson’s r-values were
signiﬁcantly inclined to be negative (Figure 2e), ascertaining that
methylation inhibits Pol III binding. Pol III genes with lowest
Pearson’s r-values (hence most negatively correlated) were nc886,
vtRNA1-2 and some tRNA genes (shown in Supplementary Figure
S8A–H, except for nc886, to be elaborated later), indicating that
these genes were regulated by a dynamic change in methylation.
During the course of tumorigenesis, global hypo-methylation and
local hyper-methylation both occur, resulting in cancer genomes
usually depleted of methylated CpGs on average (reviewed in
Ehrlich36). However, we failed to see such a propensity along the
Figure 2. CpG methylome and its relation to Pol III transcriptome in the 184-derived progression series. (a) A box plot of normalized POLR3A
ChIP-seq signals (calculated in Figure 1e) in each group of CpG sites. 1421 CpG sites in the 489 POLR3A-bound loci (occupied in at least one
HMEC culture) were sorted according to methylation values (average-β) and were categorized in ‘Low’ (βo0.25), ‘Medium’ (0.25 ⩽ βo0.50),
‘High’ (0.50 ⩽ βo0.75) and ‘Veryhigh’ (0.75 ⩽ β). The ANOVA test was used to calculate a P-value. See Supplementary Table S4 for full
information. (b) A scatter plot between Pol III binding and methylation of 489 loci (listed in Supplementary Table S5). If a locus had multiple
CpG sites, an average was calculated and used for plotting. From the distribution of data points, three hot areas were recognized and boxed.
Four outlier data points are red-highlighted and are tRNAGly-GGG (chr1), tRNACys-GCA (chr7), tRNAGlu-CTC (chr6) and tRNACys-GCA (chr7). (c)
Counts of Pol III loci (‘genuine Pol III genes’ versus ‘repeats and pseudogenes’) in the three groups of data points in (b). (d) Scatter plots of
indicated categorized Pol III genes, drawn as described in (b). (e) A shortlist of 137 CpG sites was obtained from the 1421 sites (see the main
text for details). Per each site, its methylation values and POLR3A ChIP-seq signal values were compared across the nine HMEC cultures to
calculate a Pearson correlation value. A total of 137 correlation values were sorted and categorized, and then the number of CpG sites in each
category (shown on the top of each bar) was counted and plotted.
nc886 regulation by MYC and CpG methylation
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HMEC lineage, probably because the HMEC system represented
the window of early tumorigenesis, while other reports looked
into far advanced tumors obtained from clinical samples.
nc886 is an excellent model for Pol III study
Our Pol III transcriptome and methylome analysis indicated that
methylation inhibits Pol III gene expression, and we wanted to
substantiate the molecular mechanism. As stated in the Introduc-
tion, the repetitive nature of many Pol III genes imposes a
technical problem in studying a single transcription unit.
Furthermore, 5S rRNA and tRNAs are highly abundant and stable
RNAs (Supplementary Figures S9A and B), exacerbating the
problem. Actually, although our POLR3A ChIP-seq data indicated
Pol III binding at certain conﬁned loci in certain speciﬁc HMEC
cultures, this variability was obscured when we observed the
constant steady-state RNA level of 5S rRNA (Figures 3a and b and
Supplementary Figure S10). To avoid these problems, in many Pol
III studies precursor tRNAs (pre-tRNAs) are measured. However, it
is questionable whether quantitative reverse transcriptase-PCR of
pre-tRNAs genuinely measures the transcriptional rate, because
they are processing intermediates whose steady-state levels are
very low as determined both by a transcription rate and a
maturation rate. This caveat explains why the expression of several
pre-tRNAs did not show any recognizable pattern in the HMEC
cultures (Figure 3b and Supplementary Figure S10).
nc886 is a recently identiﬁed Pol III gene whose expression level
is critical in determining cell death/proliferation by controlling the
activity of Protein Kinase R.37 nc886 expression is silenced in
several malignancies, indicating a tumor suppressor role
therein.11–14 On the other hand, nc886 plays an oncogenic role
in thyroid cancer.38 Our data from ovarian cancer (YSL,
unpublished data) indicate that nc886 suppresses proliferation
of cancer cells whereas it promotes their metastatic potential.
Between cell proliferation and metastasis, the tumorigenic role
differs according to tumor stage and determines whether nc886 is
a tumor suppressor or an oncogene in that context. Commensu-
rate with these contradictory roles, nc886 expression in cancer has
two opposite facets and is exquisitely regulated as will be
shown below.
The utilization of nc886 can circumvent aforementioned
problems as well as provide several advantages for Pol III study:
(1) it is encoded at a single genomic locus, (2) the product RNA is
not too stable (half-life = 71.5 min in Supplementary Figures S9A
and B),37 (3) the RNA expression level is high enough to be
measured reliably by Northern hybridization, (4) nc886 has a CpG
island and is epigenetically silenced, (5) nc886 is activated by MYC
(see below). Collectively, nc886 is an excellent model to
investigate Pol III regulation whose interesting aspects have been
largely concealed until now.
We began the nc886 study by characterizing it as to Pol III gene
type, because each type has a distinct promoter architecture and
Pol III subunit assembly and importantly is differently regulated by
methylation (see Supplementary Figure S5). Pol III promoters are
classiﬁed into three types; type I (for 5S rRNA), type II (for tRNAs)
and type III (for U6 snRNA) (reviewed in Schramm and
Hernandez,39 see Supplementary Figure S11A). Previous ChIP-
seq data showed that the nc886 locus is occupied by BRF1, but
not by BRF228,31 (see Supplementary Figure S11B for summary).
Because BRF2 is speciﬁc to type III (see Supplementary Figure
Figure 3. Expression of nc886 and some other Pol III genes in 184-derived progression series. (a) Northern hybridization of indicated Pol III
genes. EtBr staining is shown for equal loading. The relationship among the different HMEC cultures in the progression series is depicted by
lines and arrows on the top. (b) A heat map showing relative expression levels measured by qRT-PCR. Green and red colors indicate low and
high expression relative to 184D (yellow), calculated from 2−ΔCt values. The original ΔCt values are shown in Supplementary Figure S10.
nc886 regulation by MYC and CpG methylation
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S11A), nc886 is certainly not a type III. Type I is also highly
improbable, because nc886 lacks an intermediate element that is
seen speciﬁcally in the 5S rRNA gene (Supplementary Figure S11A
and C). Like tRNA genes, nc886 has well conserved internal
promoter elements box A and B. Also, nc886 is more similar to a
tRNA gene than 5S rRNA, in terms of signal intensities and relative
positions of three Pol III subunits; BRF1, BDP1 and POLR3D;31 see
Supplementary Figure S11B for summary). Collectively, nc886 is a
type II Pol III gene.
nc886 expression in HMEC lines
nc886 expression among the HMEC cultures was of two opposite
patterns, illustrative of its two contradictory roles in cancer as
mentioned earlier. In one arm (the 184A-series lines shown on the
left side of 184D in Figure 3a), nc886 expression was increased in
the order of malignant4immortalized4primary cells (184D and
normal breast tissue). This increase was also seen in other HMEC
progression series (240L-derived and 122L-derived HMEC lines in
Supplementary Figure S1A–C). Another Pol III gene, vtRNA1-1, was
similarly increased (Figure 3a). These data are in agreement with
previous literatures having reported that Pol III activity is elevated
in cancer.3,4,40–44 As compared with nc886, the expression of U6
snRNA was increased, but only moderately. A total of 5S rRNA
levels were relatively constitutive (Figures 3a and b and
Supplementary Figure S10). The transcription from some 5S rRNA
loci was likely to be elevated based on our ChIP-seq data and also
previous literatures;3,4 however, this elevation appeared to be
dominated by its abundance and stability, leading to a relatively
constant steady-state RNA level.
In the other arm (the 184B-series lines shown on the right side
of 184D in Figure 3a), nc886 expression was silenced in some lines
(Figures 3a and b). These nc886-silenced lines (184B5, 184B5ME
and 184FMY2) will be designated nc886− hereafter. Likewise,
nc886-expressing cells will be designated nc886+ (or nc886+ to
nc886+++++ when relative nc886 expression levels need to be
indicated). Comparison of 184B5 (nc886−) with other nc886+
immortalized lines (184A1, 184AA4, 184BE1; see Figure 1a for
lineage) suggested that a certain stochastic event during the
immortalization stage led to nc886 silencing. Once this occurred in
184B5, the silencing was maintained in its progeny, 184B5ME.
nc886 silencing in HMEC lines by CpG DNA methylation
nc886 has a CpG island at the promoter region (Figure 4a) and its
silencing by DNA hyper-methylation has been reported in several
malignancies to be of clinical signiﬁcance in patient
prognosis.11–14 nc886 silencing was also seen in some HMEC
cultures at the immortalization stage (Figures 3a and b). Of note, a
switch in the CpG methylation pattern has been shown to occur at
this stage.45 We measured CpG methylation at the nc886 region
by pyrosequencing and bisulﬁte sequencing to prove hyper-
methylation in nc886− HMEC cultures (Figures 4b and c and
Supplementary Figure S12). In addition, treatment of 5-Aza-
2'deoxycytidine (AzadC), an inhibitor for DNA methyltransferases
(DNMTs), led to re-expression of nc886 in nc886− lines (184FMY2
in Figure 4d and 184B5 to be shown later in Figure 5c). All of these
data undoubtedly showed that hyper-methylation during an
immortalization stage caused nc886 silencing in HMECs. The
nc886 hyper-methylation could not be attributed to an alteration
in DNMTs (DNMT1, DNMT3A and DNMT3B), because their
expression levels and also overall methylation levels were not
correlated with nc886 levels in the nine HMEC cultures
(Supplementary Figure S13). Our analysis of breast cancer patients
from The Cancer Genome Atlas revealed nc886 hyper-methylation
in tumor samples relative to normal breast tissues (Figure 4e),
indicating that nc886 methylation did occur in breast cancer
patients and may be of clinical signiﬁcance.
In addition to being a model Pol III gene for a mechanistic
study, nc886 has several intriguing aspects in regard to methyla-
tion. nc886 is a metastable epiallele.46 Also, nc886 shows allele-
speciﬁc methylation,14 with one allele of maternal origin being
methylated in healthy normal individuals.47 In agreement, our
bisulﬁte sequencing data showed ~ 50% methylation in 184D
which is closest lineage to the normal breast tissue. This means,
from the oncology point of view, normal individuals inherently
have loss of heterozygosity in nc886 methylation, and so aberrant
hyper-methylation of the other allele is sufﬁcient for its complete
silencing. This notion, which is well illustrated in our bisulﬁte
sequencing data of nc886− HMEC cultures relative to nc886+ 184D
(Figure 4c), explains why nc886 is so frequently silenced in
tumors.11–14 Another noteworthy point in Figure 4c is ~ 50%
methylation in the 184AA4 and 184AA3 lines (nc886+++ and
nc886+++++) similar to 184D (nc886+), indicating that the originally
methylated allele was stably maintained during HMEC tumorigen-
esis and that the elevated nc886 expression was not owing to
hypo- or de-methylation.
Next we interrogated how CpG methylation suppresses nc886.
The consensus model, based on extensive studies on Pol II genes,
is that CpG methylation leads to repressed chromatin and thereby
induces silencing (reviewed in Fuks48). This model is presupposed
to be true also for Pol III genes and is supported by a number of
references as well as our data having shown the positive
correlation of Pol III ChIP peaks with open chromatin and the
expression of neighboring genes (Supplementary Figures S7A–
D).19,28–30,32–34 Nonetheless, it is also conceivable that CpG
methylation per se might render the promoter less preferable for
Pol III binding, and this alternative possibility has been supported
by several pieces of indirect evidence. First, Pol III genes, especially
type II, on a methylated plasmid (hence in a non-chromosomal
context) were inefﬁciently transcribed when transfected into
mammalian cells, injected into Xenopus oocytes, or added in
in vitro transcription assays.8,11,12,16,17,49 Second, TFIIIC, the Pol III
subunit that recognizes type II promoter elements box A and B,
did not bind to in vitro CpG-methylated DNA.50
As shown earlier (Supplementary Figure S11C), nc886 is a type II
Pol III gene harboring box A and B, each of which contains a CpG
dinucleotide sequence (Figure 4a). We reasoned that CpG
methylation at box A and B might interfere with promoter
recognition by Pol III and tested this hypothesis by nullifying the
CpG residues via site-directed mutagenesis. Although we con-
verted the CpG residues in a way that minimally harmed the box A
and B consensus sequences (as referred in Oler et al.,28 see
Figure 4a for mutated sequences), nc886 was less efﬁciently
transcribed in mutants than the wildtype (compare lanes 3, 5, 7
and 9 in Figure 4f). Importantly, when in vitro CpG-methylated,
nc886 expression from the mutant DNA constructs was inhibited
as much as the wild-type control (lane 3–4 versus 5–10 in Figure 4f
and Supplementary Figure S14). Thus, these speciﬁc CpG residues
are critical for transcription, but their methylation is dispensable
for silencing. Taken together with previous reports,17,49 it appears
that a certain degree of CpG methylation at or near a Pol III gene,
rather than speciﬁc residues, is sufﬁcient for silencing.
We evaluated the effect of nc886 methylation on the chromatin
structure by restriction enzyme accessibility assays and ChIP
assays for methylated histones H3K4me3 and H3K27me3 as well
as acetylated histones H3K27ac, H3Ac and H4ac. In Pol III and Pol II
genes H3K4me3 and H3K27me3 are indicative of active and
inactive promoters, respectively. In several ChIP-seq data both
methylated histones have been detected as a sharp peak at the
transcription start site of Pol III genes, whereas H3K27me3 peaks
are broad in Pol II genes.30 In general, H3Ac and H4Ac are markers
for open chromatin status and therefore active transcription.
Speciﬁcally, H3K27ac is enriched in the enhancer region of Pol II
genes and is also associated with high transcriptional activity of
Pol III genes (reviewed in Park et al.6). These two assays collectively
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J-L Park et al
6
Oncogene (2017), 1 – 12 © 2017 Macmillan Publishers Limited, part of Springer Nature.
demonstrated open chromatin status of nc886+/hypo-methylated
lines (184AA3 and 184AA4) but repressed chromatin of nc886−/
hyper-methylated lines (184B5 and 184FMY2) (Figures 4g-i and
Supplementary Figure S15). In addition, AzadC treatment in the
184FMY2 line, which released nc886 from its silencing, resulted in
open chromatin status as shown by restriction enzyme accessi-
bility assays (Figure 4g). The repressed chromatin of nc886− cells
did not allow Pol III binding to the nc886 region, as proven by the
absence of nc886 in the POLR3A ChIP DNA (Figure 4j). In contrast,
the POLR3A ChIP signal was evident in nc886+ HMEC cultures.
Thus, hyper-methylation of nc886− cells is associated with
heterochromatin and lack of Pol III binding. The nc886 locus is
unlikely to form long-range heterochromatin according to our
data that its ﬂanking genes TGFBI and SMAD5 were abundantly
expressed even in nc886− HMEC cultures (Supplementary Figure
S16A) from a chromatin milieu distinct from that of nc886
nc886 regulation by MYC and CpG methylation
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Figure 5. Ampliﬁcation of nc886 expression by MYC independently of E-boxes. (a) A diagram illustrating the nc886 genomic region. Black bars
on the top depict DNA constructs for a transfection experiment in e. E-boxes (5'-CANNTG-3') are indicated by red upward arrowheads. All nt
coordinates are counted from the 5'-end of nc886 and all bars are drawn to the scale. (b) Northern hybridization of nc886 (and 5S rRNA) and
western blot of MYC (and β-actin), after transfecting siRNA against MYC. EtBr staining is also shown for Northern because 5S rRNA is known to
be affected by MYC. Protein molecular sizes from Xpert2 Prestained Protein Marker (GenDepot, Barker, TX, USA) are indicated on the right. (c)
Northern hybridization of nc886 and 5S rRNA. AzadC treatment (at 2 μM) began at day 0, siRNA transfection was at day 2 and cells were
harvested at day 4. (d) qPCR of MYC-ChIP. 2−ΔΔCt values from ChIP/input DNA were calculated from MYC-ChIP and their enrichment relative to
each IgG control is shown (y axis). The measurement was in triplicates. AzadC was treated at 2 μM for 4 days. (e) Northern hybridization after
transfecting nc886-expressing DNA constructs in a. 184FMY2 cells were transfected with none (‘mock’), non-targeting siRNA (‘si-ctrl’) and
siRNA against MYC. After 2 days, cells were harvested for MYC Western (bottom panel) and split for DNA transfection. At 24 h post transfection
of DNA, cells were harvested for Northern. The genuine nc886 band is indicated by arrowhead.
Figure 4. nc886 silencing by CpG DNA methylation. (a) A diagram depicting the nc886 genomic region. A wide nc886 locus spanning its ﬂanking
genes is on the top and two sequentially magniﬁed views are on the middle and bottom. All nt coordinates are based on the 5'-end of nc886 as
+1. (b) A bar graph of nc886 RNA expression and methylation by quantitative reverse transcriptase-PCR and pyrosequencing, respectively. RNA
expression (reclaimed from Figure 3b and S10 data) is expressed in 2−ΔCt, with the value of 184D being set as 1. Percent methylation is an average
of 4 CpG sites (#-15, − 1, 5, 20 as shown in a; see Supplementary Figure S12 for methylation of individual sites). An average and the standard
deviation from triplicates are shown. (c) Bisulﬁte sequencing results in indicated HMEC lines with their relative nc886 expression levels in
parentheses. Ten clones per each CpG site were sequenced. Open and ﬁlled circles represent unmethylated and methylated CpG dinucleotides,
respectively. (d) Northern hybridization of nc886 after 2 days of AzadC treatment. (e) A box plot of nc886 CpG methylation in 92 paired breast
tumors and non-tumors tissues from the TCGA data set. The HumanMethylation 450 K BeadChip platform included 10 CpG sites (cg04481923,
cg18678645, cg06536614, cg26328633, cg25340688, cg26896946, cg00124933, cg07845965, cg16615357 and cg18797653) at the nc886 locus. An
average of the 10 CpGs was calculated and plotted. (f) Northern hybridization at 24 h post transfecting nc886-expressing plasmid ‘pCR886(1.3k)’ or
its mutant derivatives at box A, B or both (designated as wt, Box A, BoxB and Box A/B, respectively; see also a for mutated sequences). Prior to
transfection, these plasmid DNAs were mock-treated or CpG-methylated by the M.SssI enzyme and proper methylation was assured by HhaI/HpaII
digestion of an aliquot (see Supplementary Figure S14 for details). The same transfection efﬁciency was assured by co-transfection of a plasmid
expression mut tRNA-Ser (whose mutation was needed to distinguish from endogenous tRNA signal). (g) Restriction enzyme accessibility assays.
nc886 Ct values in nested PCR were normalized to GAPDH and expressed in 2−ΔΔCt, with the value of untreated 184FMY2 line being set as 1.
Higher values indicate more AluI susceptibility owing to open chromatin structure. P-values are shown. (h) End-point PCR of nc886 and vtRNA1-1
(for comparison) on indicated ChIP DNA and input DNA. H3K4me3 and H3K27me3 are markers for open and repressed chromatin, respectively. (i)
qPCR measurement of nc886 after H3K27ac (for open chromatin) ChIP. From 2−ΔCt values from ChIP and input DNA, % bound was calculated (x
axis). (j) qPCR measurement of indicated genes after POLR3A ChIP. % bound (y axis) was calculated as in i.
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(Supplementary Figure S16B as compared with Figure 4h;
Supplementary Figure S16C). This result is interesting when
considering the CCCTC-binding factor, a barrier protein blocking
the spread of heterochromatin (reviewed in Ong and Corces51).
ENCODE ChIP-seq data indicate that there are two CCCTC-binding
factor binding sites at each side of the nc886 region; one at ~ 2 kb
upstream and the other at ~ 13 kb downstream of nc886. This
suggests that the chromatin status of nc886 is insulated by
CCCTC-binding factor, which would explain the lack of correlation
between nc886 and TGFBI/SMAD5. It should be mentioned that
these three genes might be co-regulated in other biological
contexts although they were independently expressed in HMEC
cultures. Overall, our data from nc886 are in good support of the
conventional model that hyper-methylation induces heterochro-
matin and silencing.
Activation of nc886 expression in HMEC lines by MYC
Pol III transcription is elevated in cancer and so was it in our HMEC
cultures. In the case of nc886, the elevated expression from 184D
(nc886+) to more tumorigenic cultures (nc886+++ to nc886+++++)
cannot be attributed to hypo-methylation, because all those cells
had the same 50% methylation. So, we looked into TFs, especially
MYC, because it is a potent TF and cancer driver. In fact, several of
the immortalized HMEC lines were generated with MYC transduc-
tion (Figure 1a and Supplementary Figure S1A).23,24 The MYC
expression level was the lowest in 184D (normal primary cells) but
tended to be elevated in all other immortalized or further
transformed HMEC cultures (Supplementary Figure S17). Also,
ChIP-seq data from the Encyclopedia of DNA Elements (ENCODE)
project suggested MYC binding to the nc886 region (Figure 5a).
So, we examined MYC in nc886 regulation.
Knockdown (kd) of MYC decreased the nc886 expression level
in the examined HMEC lines (Figures 5b and c) and also another
breast cancer cell line, MDA-MB-231 (nc886+++++, MYC-high;37
Supplementary Figure S18A). 5S rRNA expression is also known to
be activated by MYC, but was only marginally affected by MYC kd.
This may be because 5S rRNA is too stable (see Supplementary
Figures S9A and B) to elicit any signiﬁcant reduction within 48 h.
MYC kd resulted in less ChIP signal of POLR3A at nc886 and
vtRNA1-1 (Supplementary Figure S18B), indicating that MYC is
required for Pol III loading to promoters. We also did MYC kd in
combination with AzadC treatment (Figure 5c). When 184FMY2
(nc886−, MYC-high) was treated with AzadC, nc886 was re-
expressed to a level comparable to 184AA3 cells (nc886+++++,
MYC-high) (Figures 4d and 5c). By comparison, nc886 was restored
to a moderate expression level (nc886+ ~ ++) by AzadC treatment
in 184B5 cells (nc886−, MYC-low) (compare lane 2 and 6 in
Figure 5c). In both cell lines, MYC kd in this condition decreased
nc886 to a basal expression level (compare lane 4 and 8 in
Figure 5c) similarly to the level of 184D (nc886+, MYC-lowest
normal primary cells).
MYC binds to the recognition sequence E-box (5'-CACGTG-3').
Some TFs including MYC bind to distal loci and control
transcription via forming a long-range chromatin loop (reviewed
in Dang2, and Kadauke and Blobel52). However, this possibility is
unlikely for nc886 because chromatin interaction was not
detectable at the nc886 locus when we examined Chromatin
Interaction Analysis Paired-End Tags data and Hi-C data from the
ENCODE project (Supplementary Figures S19A and B). Based on
this and also from the feasibility of our experiments using DNA
constructs, we conﬁned our search for an E-box within the
proximal region (~2 kb) of nc886. TF prediction programs such as
PROMO v3.0 using the TRANSFAC v8.3 database53 and ConSite
(http://consite.genereg.net/) did not detect any E-box therein. So,
instead of searching for the strict E-box, we scanned the nc886
upstream region for any sequence matching to the E-box
consensus sequence (5'-CANNTG-3') and were able to ﬁnd three
sites (Figure 5a). In our ChIP data, MYC binding was evident only in
AzadC-treated 184FMY2 (Figure 5d) and was mapped near the
POLR3A ChIP-peak harboring the nc886 transcript (Figures 5a and
d) rather than in the ~ 1000 bp upstream region harboring an
E-box consensus sequence. Our data suggested that the upstream
E-boxes were dispensable, which was demonstrated by our
transfection assays (Figure 5e). We prepared two different
nc886-expressing plasmids, one with the E-boxes and the other
without them, and transfected them into 184FMY2 cells. These
two plasmids expressed comparable levels of nc886 (lane 3–4 in
Figure 5e) and both of them were similarly inhibited upon MYC kd
(lane 6–7 in Figure 5e).
Collectively, our MYC data were in good agreement with
previous studies which show that the pre-requisite for MYC
association to target promoters is an open chromatin status54 and
that MYC interacts with Pol III machinery rather than a DNA
sequence element for stimulating Pol III transcription.4 Although
we prefer this simple model, it is also possible that MYC activates
Pol III transcription via an epigenetic mechanism because MYC is
known to recruit GCN5, a histone acetyltransferase, and its
cofactor TRRAP to tRNA and 5S rRNA genes.55 However, in our
MYC kd experiments we did not observe any signiﬁcant alteration
of histone acetylation (Supplementary Figure S20) and could rule
out the requirement of MYC for maintaining the acetylation.
Nonetheless, a role of MYC for the establishment of open
chromatin structure still remains to be a plausible scenario and
waits for further investigation.
DISCUSSION
In summary, our data clariﬁed several questions about the
regulation of Pol III genes in cancer, with nc886 as a representative
case (summarized in Figure 6). Normal ﬁnite cells sustain
transcription of a subset of Pol III genes at a basal level while
increasing the Pol III repertoire as they become immortalized. The
basal level transcription of those Pol III genes is ampliﬁed by MYC
in non-malignant and malignant immortalized lines, regardless of
DNA sequence. Conversely in some other Pol III genes, hyper-
methylation and the consequent heterochromatin formation
precludes MYC and Pol III from binding to DNA. Based on our
ﬁndings here, the landscape of the Pol III transcriptome is
illustrated by methylation determining the framework and MYC
boosting the color. In addition, we speculate that other various TFs
add further details for exquisite shaping of the Pol III panorama in
cancer. Our study is the ﬁrst report to: (1) investigate the Pol III
transcriptome and methylome in early tumorigenesis and
(2) elucidate the molecular mechanism of MYC and epigenetic
regulation in a single speciﬁc Pol III transcription unit.
Figure 6. Summary cartoon illustrating the regulation of nc886 and
other Pol III genes in the HMEC tumorigenesis model.
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This study only initiates understanding of Pol III regulation,
which is far more complicated than previously thought. The three
types of Pol III genes are regulated differently as shown here and
the new information from nc886 in this study represents only type
II Pol III genes. 5S rRNA genes (type I) cannot be explained by our
simple model that hyper-methylation induces heterochromatin
formation and gene silencing. We speculate that each of several
thousands of Pol III genes are differently regulated and their
transcriptional activity affects chromatin milieu in turn. All these
questions need further investigation.
MATERIALS AND METHODS
Cell lines and other reagents
HMEC cultures were derived and grown as previously published.23–27,56,57
A complete formulation of culture medium is available upon request.
Sources of other reagents were described in Lee et al.12 and Lee et al.37
Measurement and analysis of RNA
Northern hybridization and quantitative reverse transcriptase-PCR were
performed as previously described in,37 using primers summarized in
Supplementary Table S6. Unless otherwise speciﬁed in the ﬁgure legend,
all quantitative assays (quantitative reverse transcriptase-PCR, ChIP-PCR
and so on) were done in biological triplicates for an average and the s.d.,
from which P-values were calculated by two-sided t-test.
Plasmid DNAs, siRNAs and transfection
‘pCR886(1.3k)’, a nc886-expressing plasmid, was used for transfection
experiments (Figure 4f). To construct this plasmid, a 1355 nucleotide (nt)
DNA fragment containing the nc886 genomic region (nt − 977~+378,
referring to the 5'-end nt of nc886 RNA as +1) was PCR-ampliﬁed and then
inserted into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, USA).
Plasmids containing 2362 and 1341 nt of the nc886 region (see Figure 5a)
were also made in the same manner. Since pCR4-TOPO lacks a mammalian
promoter, nc886 expression from this plasmid is entirely driven by its own
promoter. Plasmids carrying mutations at box A and/or B (see Figures 4a
and f) were made from pCR886(1.3 k) by Quikchange site-directed
mutagenesis. Prior to transfection, these plasmids were in vitro CpG-
methylated by the M.SssI enzyme, as described in Lee et al.12 ‘mut tRNA-
Ser’ (Figure 4f) was a mutant tRNA co-transfected to ascertain the same
transfection efﬁciency. We cloned a PCR-fragment containing tRNA-Ser-
TCA and its ﬂanking genomic sequence (chr10:69524104-69524441) into
pCR4-TOPO and then introduced a mutation at its anticodon loop (5′-AACT
-3′ from the wild-type sequence 5′-TTGA-3′), so that ectopically expressed
‘mut tRNA-Ser’ could be measured without interference from an
endogenous tRNA signal. All primers for PCR and mutagenesis are
summarized in Supplementary Table S6. siRNAs against MYC was a Silencer
Select siRNAs from Ambion (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
and its target sequence was 5′-gagcuaaaacggagcuuuu-3′. Plasmid DNAs
and siRNA were transfected with Lipofectamine 2000 reagent and
Lipofectamine RNAiMAX reagent (Invitrogen) respectively.
Measurement of CpG DNA methylation
Pyrosequencing of the nc886 promoter region was done as described in
Lee et al.12 The bisulﬁte sequencing procedure involved the following
steps: conversion of genomic DNA by EZ DNA Methylation-Gold Kit (Zymo
Research, Orange, CA, USA), PCR ampliﬁcation of the nc886 region (nts
− 163 to +237; Figure 4a) from the bisulﬁte-modiﬁed DNA, cloning of the
ampliﬁed DNA into pGEM-T Easy Vector (Promega, Southhampton, UK),
and DNA sequencing of randomly chosen 10 white colonies. Primers for
bisulﬁte sequencing were designed using MethPrimer (http://www.
urogene.org/methprimer/index.html) and all primer information is in
Supplementary Table S6.
Restriction endonuclease accessibility assays
Basically, this assay was to assess chromatin conformation by measuring
sensitivity to AluI restriction enzyme and the detailed procedure is
described in Park et al.58 The measured AluI site is indicated in Figure 4a
and the degree of digestion was measured by ligation-mediated PCR. All
primers (adaptor primer, universal 5′-primers and gene-speciﬁc 3′-primers)
are summarized in Supplementary Table S6. nc886 values were calculated
from Ct values and were normalized to those of GAPDH.
ChIP
ChIP assays were performed as described previously58 with minor
modiﬁcations. In brief, cells were cross-linked with 1% formaldehyde,
incubated in a swelling buffer (5 mM PIPES (pH 8.0), 85 mM KCl, 0.5%
Nonidet P-40) and subjected to sonication in Buffer A (10 mM Tris-HCl (pH
8.0), 2 mM EDTA, 0.2% sodium dodecyl sulfate) using Bioruptor (Diagenode,
Denville, NJ, USA). Chromatin samples were diluted in Buffer B (10 mM Tris-
HCl (pH 8.0), 2% Triton X-100, 280 mM NaCl, 0.2% deoxycholate) and
immunoprecipitated with antibodies against POLR3A (cat #ab96328 from
Abcam, Cambridge, MA, USA), MYC (#9402 from Cell Signaling Technology,
Danvers, MA, USA), H3K4me3 (#04-745 from EMD Millipore, Billerica, MA,
USA), H3K27me3 (#07-449 from EMD Millipore) and H3K27Ac (#ab4729
from Abcam). Chromatin-antibody complexes were pulled down by
Protein A/G Dynabeads (Invitrogen). After treating with proteinase K and
reversing the cross-link, the amounts of immuneprecipitated DNA was
measured by end-point PCR (for H3K4me3 and H3K27me3) or real-time
PCR (for POLR3A, MYC and H3K27Ac) with indicated primers in
Supplementary Table S6.
ChIP-seq
A total of 100–300 nt sized genomic libraries were generated with the
input DNA and POLR3A ChIP DNA using the TruSeq ChIP Sample Prep Kit
(Illumina, San Diego, CA, USA). In brief, input and ChIP DNA fragments were
ligated to a pair of adaptors for sequencing, size-fractioned on a 2%
agarose gel to isolate 200–300 nt fragments, and subjected to 18 cycles of
PCR. Each library was diluted to 8 pM for 76 cycles of single-read
sequencing on the Illumina NextSeq 500 per the manufacturer’s
recommended protocol. Seq reads were aligned on the human reference
genome 19 with Bowtie2, and then the bam format ﬁle was converted to
the sam format ﬁle using the SAM tools v1.4,59 ChIP-peak calling and
visualization were performed using a HOMER package using the default
parameter setting.60 Our ChIP-seq raw ﬁles are available from NCBI
Sequence Read Archive (http://www.ncbi.nih.gov/sra/) via accession
number SRP075723.
Measurement of CpG methylome
Inﬁnium MethylationEPIC BeadChip (Illumina) was used for methylation
array experiments per manufacturer’s instruction. In brief, 500 ng of
genomic DNA from nine HMEC cultures was treated with 20 μl sodium
bisulﬁte solution that was included in the EZ DNA Methylation-Gold Kit
(Zymo Research). Bisulﬁte-converted DNA (4 μl) was ampliﬁed using the
Inﬁnium Methylation Assay kit (Illumina). Ampliﬁed DNA was hybridized to
Inﬁnium MethylationEPIC BeadChip and scanned with the Illumina iSCAN
system. CpG methylation values were calculated as average-β values using
the GenomeStudio (V2010.3), per this equation: average-β=MI(M+U+100),
where M and U are methylated and unmethylated signal intensities,
respectively. Measurements with P-valueo0.05 were considered to have a
signiﬁcant signal above background. All primary methylation array data
were deposited in the GEO database under accession number GSE81939.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
This work was supported by a Research Scholar Grant, RSG-12-187-01—RMC from the
American Cancer Society to YSL; grants NRF-2012M3A9D1054670 and
NRF-2014M3C9A3068554 funded by the Ministry of Science, ICT and Future Planning
and KRIBB Research Initiative to S-YK; a grant 2016R1A2B4014183 and
2017M3C9A5029978 funded by National Research Foundation of Korea to H-PK;
National Cancer Center (Korea) intramural project # 1610090 to Y-SL; and US
Department of Energy under Contract No. DE-AC02-05CH11231 to MRS.
REFERENCES
1 White RJ. RNA polymerase III transcription and cancer. Oncogene 2004; 23:
3208–3216.
2 Dang CV. MYC on the path to cancer. Cell 2012; 149: 22–35.
nc886 regulation by MYC and CpG methylation
J-L Park et al
10
Oncogene (2017), 1 – 12 © 2017 Macmillan Publishers Limited, part of Springer Nature.
3 Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional
ampliﬁcation in tumor cells with elevated c-Myc. Cell 2012; 151: 56–67.
4 Gomez-Roman N, Grandori C, Eisenman RN, White RJ. Direct activation of RNA
polymerase III transcription by c-Myc. Nature 2003; 421: 290–294.
5 Bhargava P. Epigenetic regulation of transcription by RNA polymerase III. Biochim
Biophys Acta 2013; 1829: 1015–1025.
6 Park JL, Lee YS, Kunkeaw N, Kim SY, Kim IH, Lee YS. Epigenetic regulation of
noncoding RNA transcription by mammalian RNA polymerase III. Epigenomics
2017; 9: 171–187.
7 Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends
Biochem Sci 2006; 31: 89–97.
8 Besser D, Gotz F, Schulze-Forster K, Wagner H, Kroger H, Simon D. DNA methy-
lation inhibits transcription by RNA polymerase III of a tRNA gene, but not of a 5S
rRNA gene. FEBS Lett 1990; 269: 358–362.
9 Selvakumar T, Gjidoda A, Hovde SL, Henry RW. Regulation of human RNA
polymerase III transcription by DNMT1 and DNMT3a DNA methyltransferases.
J Biol Chem 2012; 287: 7039–7050.
10 Hu S, Wu J, Chen L, Shan G. Signals from noncoding RNAs: unconventional roles
for conventional pol III transcripts. Int J Biochem Cell Biol 2012; 44: 1847–1851.
11 Lee HS, Lee K, Jang HJ, Lee GK, Park JL, Kim SY et al. Epigenetic silencing of the
non-coding RNA nc886 provokes oncogenes during human esophageal tumor-
igenesis. Oncotarget 2014; 5: 3472–3481.
12 Lee KS, Park JL, Lee K, Richardson LE, Johnson BH, Lee HS et al. nc886, a non-
coding RNA of anti-proliferative role, is suppressed by CpG DNA methylation in
human gastric cancer. Oncotarget 2014; 5: 3944–3955.
13 Cao J, Song Y, Bi N, Shen J, Liu W, Fan J et al. DNA methylation-mediated
repression of miR-886-3p predicts poor outcome of human small cell lung cancer.
Cancer Res 2013; 73: 3326–3335.
14 Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C et al. Allelic
methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1
predict outcome in AML. Blood 2012; 119: 206–216.
15 Liu WM, Maraia RJ, Rubin CM, Schmid CW. Alu transcripts: cytoplasmic localisation
and regulation by DNA methylation. Nucleic Acids Res 1994; 22: 1087–1095.
16 Banati F, Koroknai A, Salamon D, Takacs M, Minarovits-Kormuta S, Wolf H et al.
CpG-methylation silences the activity of the RNA polymerase III transcribed
EBER-1 promoter of Epstein-Barr virus. FEBS Lett 2008; 582: 705–709.
17 Juttermann R, Hosokawa K, Kochanek S, Doerﬂer W. Adenovirus type 2 VAI RNA
transcription by polymerase III is blocked by sequence-speciﬁc methylation. J Virol
1991; 65: 1735–1742.
18 Xie H, Wang M, Bonaldo Mde F, Rajaram V, Stellpﬂug W, Smith C et al. Epigenomic
analysis of Alu repeats in human ependymomas. Proc Natl Acad Sci USA 2010; 107:
6952–6957.
19 Varshney D, Vavrova-Anderson J, Oler AJ, Cowling VH, Cairns BR, White RJ. SINE
transcription by RNA polymerase III is suppressed by histone methylation but not
by DNA methylation. Nat Commun 2015; 6: 6569.
20 Fu Y, Lee I, Lee YS, Bao X. Small non-coding transfer RNA-derived RNA fragments
(tRFs): their biogenesis, function and implication in human diseases. Genomics
Inform 2015; 13: 94–101.
21 Stampfer MR, LaBarge MA, Garbe JC. An integrated human mammary epithelial
cell culture System for studying carcinogenesis and aging. In: Schatten H (ed). Cell
Mol Biol Breast Cancer. Springer: NY, USA, 2013, pp 323–361.
22 Hines WC, Kuhn I, Thi K, Chu B, Stanford-Moore G, Sampayo R et al. 184AA3: a
xenograft model of ER+ breast adenocarcinoma. Breast Cancer Res Treat 2016;
155: 37–52.
23 Lee JK, Garbe JC, Vrba L, Miyano M, Futscher BW, Stampfer MR et al. Age and the
means of bypassing stasis inﬂuence the intrinsic subtype of immortalized human
mammary epithelial cells. Front Cell Dev Biol 2015; 3: 13.
24 Garbe JC, Vrba L, Sputova K, Fuchs L, Novak P, Brothman AR et al. Immortalization
of normal human mammary epithelial cells in two steps by direct targeting of
senescence barriers does not require gross genomic alterations. Cell Cycle 2014;
13: 3423–3435.
25 Garbe JC, Bhattacharya S, Merchant B, Bassett E, Swisshelm K, Feiler HS et al.
Molecular distinctions between stasis and telomere attrition senescence barriers
shown by long-term culture of normal human mammary epithelial cells. Cancer
Res 2009; 69: 7557–7568.
26 Stampfer MR, Garbe J, Nijjar T, Wigington D, Swisshelm K, Yaswen P. Loss of p53
function accelerates acquisition of telomerase activity in indeﬁnite lifespan
human mammary epithelial cell lines. Oncogene 2003; 22: 5238–5251.
27 Stampfer MR, Bartley JC. Induction of transformation and continuous cell lines
from normal human mammary epithelial cells after exposure to benzo[a]pyrene.
Proc Natl Acad Sci USA 1985; 82: 2394–2398.
28 Oler AJ, Alla RK, Roberts DN, Wong A, Hollenhorst PC, Chandler KJ et al. Human
RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin
and enhancer-binding factors. Nat Struct Mol Biol 2010; 17: 620–628.
29 Alla RK, Cairns BR. RNA polymerase III transcriptomes in human embryonic stem
cells and induced pluripotent stem cells, and relationships with pluripotency
transcription factors. PLoS ONE 2014; 9: e85648.
30 Barski A, Chepelev I, Liko D, Cuddapah S, Fleming AB, Birch J et al. Pol II and its
associated epigenetic marks are present at Pol III-transcribed noncoding
RNA genes. Nat Struct Mol Biol 2010; 17: 629–634.
31 Canella D, Praz V, Reina JH, Cousin P, Hernandez N. Deﬁning the RNA polymerase
III transcriptome: genome-wide localization of the RNA polymerase III transcrip-
tion machinery in human cells. Genome Res 2010; 20: 710–721.
32 Carriere L, Graziani S, Alibert O, Ghavi-Helm Y, Boussouar F, Humbertclaude H
et al. Genomic binding of Pol III transcription machinery and relationship with
TFIIS transcription factor distribution in mouse embryonic stem cells. Nucleic Acids
Res 2012; 40: 270–283.
33 Moqtaderi Z, Wang J, Raha D, White RJ, Snyder M, Weng Z et al. Genomic binding
proﬁles of functionally distinct RNA polymerase III transcription complexes in
human cells. Nat Struct Mol Biol 2010; 17: 635–640.
34 Canella D, Bernasconi D, Gilardi F, LeMartelot G, Migliavacca E, Praz V et al. A
multiplicity of factors contributes to selective RNA polymerase III occupancy
of a subset of RNA polymerase III genes in mouse liver. Genome Res 2012; 22:
666–680.
35 Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev
2011; 25: 1010–1022.
36 Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene
2002; 21: 5400–5413.
37 Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY et al. Precursor miR-886, a
novel noncoding RNA repressed in cancer, associates with PKR and modulates its
activity. RNA 2011; 17: 1076–1089.
38 Lee EK, Hong SH, Shin S, Lee HS, Lee JS, Park EJ et al. nc886, a non-coding RNA
and suppressor of PKR, exerts an oncogenic function in thyroid cancer. Onco-
target 2016; 7: 75000–75012.
39 Schramm L, Hernandez N. Recruitment of RNA polymerase III to its target pro-
moters. Genes Dev 2002; 16: 2593–2620.
40 Felton-Edkins ZA, Kenneth NS, Brown TR, Daly NL, Gomez-Roman N, Grandori C
et al. Direct regulation of RNA polymerase III transcription by RB, p53 and c-Myc.
Cell Cycle 2003; 2: 181–184.
41 Winter AG, Sourvinos G, Allison SJ, Tosh K, Scott PH, Spandidos DA et al. RNA
polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors. Proc
Natl Acad Sci USA 2000; 97: 12619–12624.
42 Felton-Edkins ZA, White RJ. Multiple mechanisms contribute to the activation of
RNA polymerase III transcription in cells transformed by papovaviruses. J Biol
Chem 2002; 277: 48182–48191.
43 Chen W, Bocker W, Brosius J, Tiedge H. Expression of neural BC200 RNA in human
tumours. J Pathol 1997; 183: 345–351.
44 Chen W, Heierhorst J, Brosius J, Tiedge H. Expression of neural BC1 RNA: induction
in murine tumours. Eur J Cancer 1997; 33: 288–292.
45 Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW. Stepwise
DNA methylation changes are linked to escape from deﬁned proliferation
barriers and mammary epithelial cell immortalization. Cancer Res 2009; 69:
5251–5258.
46 Silver MJ, Kessler NJ, Hennig BJ, Dominguez-Salas P, Laritsky E, Baker MS et al.
Independent genomewide screens identify the tumor suppressor VTRNA2-1 as a
human epiallele responsive to periconceptional environment. Genome Biol 2015;
16: 118.
47 Romanelli V, Nakabayashi K, Vizoso M, Moran S, Iglesias-Platas I, Sugahara N et al.
Variable maternal methylation overlapping the nc886/vtRNA2-1 locus is locked
between hypermethylated repeats and is frequently altered in cancer. Epigenetics
2014; 9: 783–790.
48 Fuks F. DNA methylation and histone modiﬁcations: teaming up to silence genes.
Curr Opin Genet Dev 2005; 15: 490–495.
49 Liu WM, Schmid CW. Proposed roles for DNA methylation in Alu transcriptional
repression and mutational inactivation. Nucleic Acids Res 1993; 21: 1351–1359.
50 Bartke T, Vermeulen M, Xhemalce B, Robson SC, Mann M, Kouzarides T.
Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell
2010; 143: 470–484.
51 Ong CT, Corces VG. CTCF: an architectural protein bridging genome topology and
function. Nat Rev Genet 2014; 15: 234–246.
52 Kadauke S, Blobel GA. Chromatin loops in gene regulation. Biochim Biophys Acta
2009; 1789: 17–25.
53 Messeguer X, Escudero R, Farre D, Nunez O, Martinez J, Alba MM. PROMO:
detection of known transcription regulatory elements using species-tailored
searches. Bioinformatics 2002; 18: 333–334.
54 Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V et al.
Myc-binding-site recognition in the human genome is determined by chromatin
context. Nat Cell Biol 2006; 8: 764–770.
nc886 regulation by MYC and CpG methylation
J-L Park et al
11
© 2017 Macmillan Publishers Limited, part of Springer Nature. Oncogene (2017), 1 – 12
55 Kenneth NS, Ramsbottom BA, Gomez-Roman N, Marshall L, Cole PA, White RJ.
TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription.
Proc Natl Acad Sci USA 2007; 104: 14917–14922.
56 Labarge MA, Garbe JC, Stampfer MR. Processing of human reduction mammo-
plasty and mastectomy tissues for cell culture. J Vis Exp 2013; doi: 10.3791/50011.
57 Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR. Inactivation of p53 function in
cultured human mammary epithelial cells turns the telomere-length dependent
senescence barrier from agonescence into crisis. Cell Cycle 2007; 6: 1927–1936.
58 Park K, Park JH, Yang WJ, Lee JJ, Song MJ, Kim HP. Transcriptional activation of the
IL31 gene by NFAT and STAT6. J Leukoc Biol 2012; 91: 245–257.
59 Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. The Sequence
Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078–2079.
60 Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. Simple combinations
of lineage-determining transcription factors prime cis-regulatory
elements required for macrophage and B cell identities. Mol Cell 2010; 38:
576–589.
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
nc886 regulation by MYC and CpG methylation
J-L Park et al
12
Oncogene (2017), 1 – 12 © 2017 Macmillan Publishers Limited, part of Springer Nature.
